P/B
6,8
Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
$505.7M
Market Cap • 9/11/2026
2018
(8 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United Kingdom
Country
Valuation
P/S
4,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,3
EPS
—
Market Cap
Market Cap
505,7M
EV
387,6M
EV/Revenue
3,3
EV/EBITDA
-1,6
EV/EBIT
-1,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-1,5B
Profitability
Gross Margin
15,7%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
95,9%
Capex/Revenue
6,6%
Capex/D&A
69,3%
Capex/OCF
-11,7%
SBC/OCF
—
% PPE
27,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
131,9%
CAGR Op. Income 5Y
7,9%
CAGR Net Income 5Y
13,8%
CAGR EPS 5Y
-16,1%
CAGR OCF 5Y
-14,9%
Leverage
N.D./EBITDA
0,5
Debt/Equity
0%
Current Ratio
4,9
Quick Ratio
3,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!